Semaglutide: Dosing Protocols

Prescribing Information#

Semaglutide is an FDA-approved prescription medication marketed as Ozempic (injectable, type 2 diabetes), Wegovy (injectable, weight management), and Rybelsus (oral, type 2 diabetes). All dosing information below is based on FDA-approved prescribing information and clinical trial protocols. Semaglutide must be prescribed and supervised by a qualified healthcare provider.

Injectable Dose Escalation: Ozempic (Type 2 Diabetes)#

Starting Dose#

All patients begin with 0.25 mg administered once weekly by subcutaneous injection for the first 4 weeks. The 0.25 mg dose is not intended as a therapeutic dose for glycemic control; it serves as a tolerability-building dose that allows the gastrointestinal system to adapt to GLP-1 receptor activation.

Escalation Steps#

The 0.5 mg dose is the minimum therapeutic dose. Most patients achieve adequate glycemic control at 0.5 mg or 1 mg. The 2 mg dose, approved in 2022, provides incremental HbA1c reduction for patients needing additional glycemic control beyond 1 mg.

Clinical Outcomes by Dose (SUSTAIN Trials)#

• 0.5 mg weekly: HbA1c reduction of approximately 1.2-1.5%
• 1 mg weekly: HbA1c reduction of approximately 1.5-1.8%
• 2 mg weekly: HbA1c reduction of approximately 2.0-2.2% (SUSTAIN FORTE)

Injectable Dose Escalation: Wegovy (Weight Management)#

Escalation Schedule#

Wegovy uses a more gradual 16-week escalation to the 2.4 mg maintenance dose:

The maintenance dose of 2.4 mg is the target for weight management. This dose was used in the STEP clinical trials and provides the greatest weight reduction. If a patient cannot tolerate 2.4 mg, maintenance at 1.7 mg may be considered, though weight loss efficacy will be reduced.

Clinical Outcomes (STEP Trials)#

• STEP 1: 2.4 mg weekly achieved 14.9% mean weight loss at 68 weeks (vs 2.4% placebo)
• STEP 2 (with T2D): 2.4 mg weekly achieved 9.6% mean weight loss
• STEP 3 (with lifestyle intervention): 2.4 mg weekly achieved 16.0% mean weight loss
• STEP 5 (2-year data): 2.4 mg weekly maintained 15.2% weight loss at 104 weeks

Oral Dosing: Rybelsus (Type 2 Diabetes)#

Dose Escalation#

Critical Administration Requirements#

Rybelsus must be taken under specific conditions to ensure absorption, as oral peptide bioavailability is inherently low (approximately 0.4-1%):

1. Fasting: Take on an empty stomach, first thing in the morning
2. Water only: Swallow whole with no more than 4 oz (120 mL) of plain water
3. Wait 30 minutes: Do not eat, drink other beverages, or take other oral medications for at least 30 minutes
4. Do not split or crush: Tablet must be swallowed whole; the SNAC absorption enhancer requires intact tablet contact with gastric mucosa

Failure to follow these instructions significantly reduces absorption and therapeutic effect.

Administration Technique (Injectable)#

Pre-Filled Pen Devices#

Ozempic: Multi-dose pen containing multiple weekly doses. Available in two pen configurations:

• 2 mg/1.5 mL pen: delivers 0.25 mg or 0.5 mg doses
• 4 mg/3 mL pen: delivers 1 mg doses
• 8 mg/3 mL pen: delivers 2 mg doses

Each pen includes disposable pen needles that are attached before each injection.

Wegovy: Single-dose pre-filled pen. One pen per injection. Available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg strengths.

Injection Procedure#

1. Preparation: Remove pen from refrigeration and allow to reach room temperature (approximately 30 minutes). For Ozempic, attach a new pen needle. Inspect the solution: it should be clear and colorless. Do not use if cloudy, discolored, or containing particles.

2. Site selection: Choose an injection site on the abdomen (at least 2 inches from the navel), front of the thigh, or back of the upper arm. Rotate sites with each injection.

3. Injection: Insert the needle into the skin, press the dose button, and hold for 6 seconds (Ozempic) or until the dose counter returns to 0 to ensure complete delivery.

4. Disposal: Remove needle and dispose in a sharps container. Replace pen cap for Ozempic multi-dose pens. Discard Wegovy single-dose pens after use.

Timing and Missed Doses#

• Dosing day: Administer on the same day each week, at any time of day, without regard to meals
• Changing dosing day: The day may be changed as long as at least 2 days (48 hours) have elapsed since the last dose
• Missed dose (injectable): If missed by fewer than 5 days, administer as soon as possible. If more than 5 days have passed, skip the missed dose and resume on the next scheduled day
• Missed dose (oral): If a daily dose is missed, skip it and take the next dose the following day. Do not double the dose.

Storage Requirements#

Ozempic (Multi-Dose Injectable Pen)#

• Before first use: Refrigerate at 2-8 degrees C. Do not freeze.
• After first use: Store at room temperature (up to 30 degrees C) or refrigerated for up to 56 days. The 56-day in-use period is longer than many other injectable GLP-1 agonists.
• Protect from direct heat and sunlight. Keep pen cap on when not in use.

Wegovy (Single-Dose Injectable Pen)#

• Store refrigerated at 2-8 degrees C. Do not freeze.
• If needed, may be stored at room temperature (up to 30 degrees C) for up to 28 days.
• Single-use pens; discard after injection.

Rybelsus (Oral Tablets)#

• Store at room temperature up to 30 degrees C (86 degrees F)
• Keep in original blister packaging to protect from moisture
• Do not transfer to pill organizers or other containers

Special Dosing Considerations#

Renal Impairment#

No dose adjustment is recommended for any degree of renal impairment, including end-stage renal disease. However, GI adverse events causing dehydration may increase the risk of acute kidney injury; adequate hydration should be maintained.

Hepatic Impairment#

No dose adjustment is required. Clinical pharmacology studies showed no clinically meaningful effect of hepatic impairment on semaglutide pharmacokinetics.

Elderly Patients#

No dose adjustment required based on age. Clinical trials included patients over 65 with comparable efficacy and safety profiles.

Concomitant Insulin or Sulfonylurea#

When adding semaglutide to insulin or sulfonylurea therapy, consider reducing the dose of the concomitant medication to reduce hypoglycemia risk. Monitor blood glucose and adjust accordingly.

Switching Between Formulations#

Patients switching from Ozempic to Wegovy (or vice versa) at equivalent doses may do so on the next scheduled dosing day. When switching between injectable and oral formulations, the oral formulation should begin 1 day after the last injection (accounting for the different pharmacokinetic profiles).

Clinical Dosing Outcomes Summary#

Related Reading#

• Semaglutide overview and research guide
• Semaglutide side effects profile
• Semaglutide research evidence